Gagnon Robert E.
SEC-identified person · CIK 1504983 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Harvard Bioscience INC HBIO | Director · Chief Financial Officer | filed 2013 - 2026 |
| Rexahn Pharmaceuticals, INC. RXHN.OB | Chief Financial Officer | filed 2025 - 2026 |
| Purple Biotech LTD. PPBT | Director | filed 2026 - 2026 |
| Verastem, Inc. VSTM | Director · Chief Financial Officer | filed 2018 - 2025 |
| Bone Biologics, Corp. BBLG | Director | filed 2024 - 2025 |
| Clean Harbors INC CLHB | EVP CFO and Treasurer | filed 2012 - 2012 |
| Biogen INC. BIIB | Vice President, Finance | filed 2010 - 2012 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.